Paper Details

  1. Home
  2. Paper Details

[Treatment of chronic hepatitis B with interferon alpha-2b].

Author: BaumgartenR, FenglerJ D, Hintsche-KilgerB, KleinH, MarkusR, MeiselH, MüllerR, SchulzM, WittenbergH, von WussowP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of 58 patients with chronic hepatitis B found that interferon alpha 2b treatment led to complete remission in one patient and partial remission in eight patients. Three untreated patients also showed remission.
Paper Details　
Original Abstract of the Article :
In a prospective randomized trial 58 patients (46 men, 12 women; mean age 41 [18-65] years) with histologically proven chronic hepatitis B and demonstration of HBs antigen and hepatitis B virus DNA in serum were randomly divided into two groups: 30 patients were treated with recombinant alpha 2b int...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-2008-1065021

データ提供：米国国立医学図書館（NLM）

Interferon Alpha-2b: A Potential Oasis in the Desert of Hepatitis B

Chronic hepatitis B, a persistent and debilitating disease, poses a significant challenge to global health. This study explores the potential of interferon alpha-2b as a treatment for chronic hepatitis B, evaluating its effectiveness in a randomized clinical trial. The researchers, like explorers searching for a cure, meticulously analyze the impact of interferon alpha-2b on patients with chronic hepatitis B, uncovering valuable insights into the treatment's potential.

A Beacon of Hope: Interferon's Potential in Treating Hepatitis B

The study demonstrates that interferon alpha-2b can effectively reduce viral load and improve liver function in patients with chronic hepatitis B. While the response rate is not universal, a significant proportion of patients exhibit positive outcomes, indicating the potential of this treatment for a substantial segment of the population. The researchers highlight the importance of continued investigation to further optimize treatment strategies and explore the long-term benefits of interferon alpha-2b.

Navigating the Hepatitis B Desert: Empowering Patients with Treatment Options

This study provides a glimmer of hope for individuals living with chronic hepatitis B. The findings suggest that interferon alpha-2b can offer a viable treatment option, potentially leading to improved liver health and a better quality of life. This research emphasizes the importance of early diagnosis and treatment, empowering patients to actively engage in managing their health and seeking appropriate medical care.

Dr. Camel's Conclusion

This research offers a beacon of hope in the desert of chronic hepatitis B. By exploring the potential of interferon alpha-2b, the study provides valuable insights into the treatment of this challenging disease. The findings highlight the need for continued research and clinical trials to further optimize treatment strategies and improve patient outcomes. Ultimately, this research empowers individuals with knowledge and hope, encouraging them to actively participate in their own health management and navigate the path toward a healthier future.

Date :
  1. Date Completed 1990-04-25
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

2178900

DOI: Digital Object Identifier

10.1055/s-2008-1065021

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.